Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19946521 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL146933 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL6327 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Bromide SCHEMBL4425101 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL29179 | 0.95 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL3930010 | 0.92 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL9322645 | 0.92 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL30770772 | 0.92 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL2920316 | 0.92 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL689027 | 0.92 | TDP1 (0.43) | CYP3A4TDP1KDM4EGAAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| US-7355053-B2 | 1-phenylpyrrolidine-2-one-3-carboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20060019831-A1 | 1-phenylpyrrolidine-2-one-3-carboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | CYP3A4 61/4885TDP1 3931/4885KDM4E 1741/4885 |
| US-20060019831-A1 | 1-phenylpyrrolidine-2-one-3-carboxamides | RXFP1, REN, NPY1R | CYP3A4 3036/4885TDP1 942/4885KDM4E 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.